Tag: HFpEF
-
Knowledge Domain and Emerging Trends on Dapagliflozin for Heart Failure: A Bibliometric Analysis (2012–2024)
Introduction Dapagliflozin, a leading SGLT2 inhibitor, has evolved from a glucose-lowering agent to a cornerstone therapy for heart failure (HF). Built on pivotal trials like DAPA-HF and DELIVER, dapagliflozin now targets a broad spectrum of HF patients, including those without diabetes. A recent bibliometric analysis of literature from 2012 to 2024 maps the global research…
-
Knowledge Domain and Emerging Trends on Dapagliflozin for Heart Failure: A Bibliometric View (2012–2024)
Introduction: Dapagliflozin as a Cornerstone in Heart Failure Therapy Heart failure (HF) remains a global healthcare challenge with rising prevalence and substantial economic burden. Dapagliflozin, an SGLT2 inhibitor, emerged as a pivotal therapy beyond glucose control, driven by landmark trials such as DAPA-HF. A bibliometric analysis of research from 2012 to 2024 reveals how scientific…
-
Knowledge Gaps and Emerging Trends in Dapagliflozin for Heart Failure: A 2012–2024 Bibliometric Analysis
Introduction Dapagliflozin, a pioneering SGLT2 inhibitor, has evolved from a diabetes medication to a cornerstone therapy for heart failure (HF). Built on pivotal trials such as DAPA-HF and DELIVER, its role now spans reduced and preserved ejection fraction HF subtypes, with ongoing investigations into cardiorenal protection and fibrosis modulation. This article interprets a comprehensive bibliometric…
-
New ACC Program Aims to Educate Clinicians on the Latest Advances in Heart Failure Treatment
Overview: Transforming Heart Failure Care Heart failure (HF) remains a leading cause of hospitalization and a significant public health challenge, with more than 6 million Americans affected. The American College of Cardiology (ACC) has launched a new educational initiative, Transformation of HF Care: New Horizons in Treatment, designed to equip clinicians with the latest advances…
-
Transformation of Heart Failure Care: New Horizons in Treatment for Clinicians
Introduction: A New Educational Era in Heart Failure Care The American College of Cardiology (ACC) is launching Transformation of HF Care: New Horizons in Treatment, an 18-month program designed to equip clinicians with the latest advances in heart failure (HF) management. As the disease remains a leading cause of hospitalization and increasingly affects diverse populations,…